尿激酶溶栓途径改进对急性心肌梗死患者再灌注率的影响

摘要

目的 探讨尿激酶溶栓途径改进对急性心肌梗死患者再灌注率的影响.方法 选取2013年5月至2015年6月本院收治的90例急性心肌梗死患者为研究对象,采用随机数表法分为观察组和对照组各45例,对照组给予常规尿激酶溶栓途径治疗,观察组采用改进的尿激酶溶栓途径(包括给药剂量、给药部位等方面的改进)治疗,比较两组左室射血分数(LVEF)、左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)评价心功能,同时分析两组再灌注率、并发症发生率.结果 治疗后观察组LVEF为(61.94±1.54)％、LVESV为(4.67±0.66) cm、LVEDV为(3.67±0.22)cm高于对照组(P＜0.05);观察组再灌注率高于对照组(48.89％比33.33％)(P＜0.05),而其并发症发生率与对照组(8.89％比26.67％)比较明显较低(P＜0.05).结论 改进尿激酶溶栓途径可明显提高急性心肌梗死患者再灌注率,降低不良事件,值得在临床推广应用.%Objective To investigate the effect of modified urokinase thrombolytic approach on the reperfusion rate in patients with acute myocardial infarction.Methods Ninety patients with acute myocardial infarction admitted to our hospital from May 2013 to June 2015 were selected as study subjects,and divided into observation group and control group by the random number table method,45 cases in each group.The control group was treated with routine urokinase thrombolytic approach,while the observation group was treated with modified urokinase thrombolytic approach (including dosage and site).Left ventricular ejection fraction (LVEF),left ventricular end systolic volume (LVESV),and left ventricular end diastolic volume (LVEDV) were compared between the two groups to evaluate the cardiac function.The reperfusion rate and the incidence of complications were analyzed.Results After treatment,LVEF [(61.94±1.54)％],LVESV [(4.67±0.66)cm],and LVEDV [(3.67±0.22)cm] of observation group were higher than those of control group (P＜0.05).The rate of reperfusion in observation group (48.89％) was higher than that in control group (33.33％) (P＜0.05),and the incidence of complications (8.89％) was significantly lower than that in control group (26.67％) (P＜0.05).Conclusion The modified urokinase thrombolytic approach can significantly improve the reperfusion rate in patients with acute myocardial infarction,and reduce the incidence of adverse events.